Complete or near-complete skin clearance has emerged as the top priority for patients choosing a systemic therapy for moderate-to-severe psoriasis, according to a report compiled for medical professionals.

The finding reframes how clinicians should structure shared decision-making when discussing systemic options, where the menu now spans injectable biologics, oral small molecules and older systemic agents with markedly different efficacy, safety and access profiles. A single decision point now carries clinical, psychological and economic weight.

What does "clearance" mean to patients?

In psoriasis trials, skin clearance is quantified using the Psoriasis Area and Severity Index (PASI). PASI 75 — a 75% reduction from baseline — defined the first generation of biologic efficacy. PASI 90 and PASI 100 (complete clearance) are now the benchmarks patients ask about at the point of care. Patient-reported outcomes such as the Dermatology Life Quality Index (DLQI) have tracked parallel improvements, reinforcing that visible clearance drives the largest gains in daily functioning, sleep and work productivity.

When patients in the report ranked their priorities, skin clearance outranked dosing frequency, route of administration and out-of-pocket cost. That ordering matters because it runs counter to how formulary committees and many clinicians historically framed the trade-off, often privileging safety record, convenience or payer-preferred status.

Why does preference ordering shift the conversation?

A patient who arrives asking for PASI 90-or-better results is a different starting point than one who asks which pill is "safest." Counseling still covers infection risk, laboratory monitoring, tuberculosis screening, vaccination history and biologic switching protocols, but the therapeutic target is set by the patient's own threshold for acceptable residual disease. That target is then tested at week 12 or 16 against the real-world response, and the conversation pivots to switching rather than waiting.

The data also reshape step-therapy negotiations with payers. Documented PASI 90 outcomes and high DLQI scores give clinicians a quantitative anchor when appealing a denial or requesting a non-preferred agent. In markets where IL-23 inhibitors, IL-17 inhibitors and TNF blockers each carry different prior-authorization criteria, patient-stated clearance goals can move a request to a higher tier.

What still needs clarifying?

The report does not specify sample size, country, language of administration, or how "preference" was elicited. Discrete-choice experiments, rank-order surveys and best-worst scaling produce different rankings, so the methodology will determine how portable the conclusion is to any given practice. Cost-sharing, prior-authorization burden and comorbid psoriatic arthritis — a factor that often pushes a patient toward an IL-17 or IL-23 inhibitor — were not addressed in the available summary. Demographic variables such as age, skin phototype and disease duration also typically modulate preferences and were not detailed.

Practices that already document patient-stated treatment goals at intake will be best positioned to act on this signal. Those that default to PASI 75 as "good enough" should expect more pushback at the next visit, and they should be ready to translate "I want clear skin" into a measurable endpoint.

The next step is integrating that patient-stated clearance threshold into the same clinical note that already records PASI, body surface area and DLQI — making preference, not just disease severity, a reimbursable, auditable input in psoriasis care.